Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1952044 | 1.00 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| SCHEMBL78923 | 1.00 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| SCHEMBL30458009 | 1.00 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| Hydrochloric Acid SCHEMBL311371 | 0.98 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| Hydrochloric Acid SCHEMBL78220 | 0.98 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| Hydrochloric Acid SCHEMBL1951786 | 0.98 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| Acetic Acid SCHEMBL5167209 | 0.94 | SLC7A5 (0.38) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| SCHEMBL569252 | 0.84 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| SCHEMBL3294154 | 0.84 | NOS1 (0.42) | NOS1NOS3NOS2LTA4HSLC1A3 | |
| SCHEMBL20503360 | 0.84 | DGAT1 (0.32) | NOS1NOS3NOS2SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230194983-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-115989235-A | Methods of treating respiratory diseases using amino acid compounds | 普利安特治疗公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10669280-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10428075-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| CN-110099682-A | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2019-08-06 | — | — | CN | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| EP-3197891-B1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | Bayer Pharma AG (DE) | 2018-11-21 | — | — | EP | disclosed |
| CN-108290879-A | Heteroaryl compound and application thereof as IRAK inhibitor | 默克专利有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1244626-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1171127-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | Targacept, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001042216-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-0804468-A1 | CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED PEPTIDE ANALOG | PEPTOR LTD (IL) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995033765-A1 | CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED PEPTIDE ANALOG | PEPTOR LTD. (IL) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669280-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | NOS1 4409/4885NOS3 3823/4885NOS2 3945/4885 |
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | F13B, TFPI, TFPI2 | NOS1 4230/4885NOS3 3143/4885NOS2 4085/4885 |
| US-10428075-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | NOS1 4409/4885NOS3 3823/4885NOS2 3945/4885 |
| US-20230194983-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | RER1, TERB1, TRRAP | NOS1 3803/4885NOS3 4177/4885NOS2 4269/4885 |
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | NOS1 126/4885NOS3 77/4885NOS2 150/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | NOS1 3193/4885NOS3 1394/4885NOS2 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.